15Dec 2022
Efficacy and Safety of ABBV‐3373, a Novel Anti‐Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody Drug Conjugate, in Adults with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy: a Randomized, Double‐Blind, Active‐Controlled Proof‐of‐Concept Phase 2a Trial

Efficacy and Safety of ABBV‐3373, a Novel Anti‐Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody Drug Conjugate, in Adults with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy: a Randomized, Double‐Blind, Active‐Controlled Proof‐of‐Concept Phase 2a Trial

To assess the efficacy and safety of ABBV‐3373, a novel antibody-drug conjugate (ADC) composed of the anti‐tumor necrosis factor (TNF) monoclonal antibody adalimumab linked to a glucocorticoid receptor modulator (GRM), versus adalimumab in patients with rheumatoid arthritis (RA). After increasing the duration of ABBV‐3373 IV administration from 3 min to 15‐30 min, no similar events of anaphylactic shock were reported. Data from this proof‐of‐concept trial support the continued development of a TNF‐GRM‐ADC for the treatment of RA, with the potential to achieve superior outcomes compared to currently available therapies.

  • #orthopaedics

Like

Save

Share